Medmira Inc (TSE:MIR)
:MIR
MIR Stock Chart & Stats
C$0.07
C$0.01(8.70%)
At close: 4:00 PM EST
C$0.07
C$0.01(8.70%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.11
Previous CloseN/A
Volume74.70K
Average Volume (3M)94.91K
Market Cap
C$44.21M
Enterprise ValueC$62.41M
Total Cash (Recent Filing)C$0.00
Total Debt (Recent Filing)C$17.07M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Jul 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding701,730,600
10 Day Avg. Volume79,718
30 Day Avg. Volume94,909
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)-2.47
Price to Sales (P/S)232.06
P/FCF Ratio-17.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformMedMira’s proprietary Rapid Vertical Flow Technology is a durable competitive asset: it enables multiple rapid-test formats, supports internal product development and third-party licensing, and creates technical differentiation that can sustain market access and partnership opportunities over months as new assays leverage the same platform.
Recurring Consumables ModelThe core business model sells IVD test kits and consumables that generate repeat orders, and distribution channels expand reach. Once adoption scales, consumable-driven recurring revenue and distributor purchase patterns can provide predictable demand and margins that persist beyond short-term market swings.
Commercialized POC Product PortfolioMedMira already commercializes POC HIV and HCV tests, showing regulatory and go-to-market execution. Existing product sales and established use cases with clinics and public-health programs reduce time-to-market for adjacent assays and make commercial scale and partnership expansion more achievable over the next several months.
Bears Say
Negative Equity And High LeverageNegative equity and heavy debt relative to assets materially weaken the balance sheet, reducing financial flexibility and increasing insolvency risk. This elevated leverage makes the company reliant on external financing or restructuring, limiting ability to invest in commercialization or weather shocks in the 2–6 month horizon.
Consistent Cash BurnSustained negative operating and free cash flow, with worsening FCF, indicates ongoing cash burn and dependence on external capital. Rising burn constrains R&D, manufacturing scale-up and commercial spend, and increases likelihood of dilutive financings or operational limitations within months if cash generation does not improve.
Weak Revenue And Falling MarginsVery small and slightly declining revenue combined with sharply worsening gross margins point to deteriorating unit economics. This undermines the pathway to sustainable profitability, makes scaling harder without structural changes, and increases the risk that commercial products cannot cover costs over the medium term.
Medmira News
MIR FAQ
What was Medmira Inc’s price range in the past 12 months?
Medmira Inc lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is Medmira Inc’s market cap?
Medmira Inc’s market cap is C$44.21M.
When is Medmira Inc’s upcoming earnings report date?
Medmira Inc’s upcoming earnings report date is Jul 07, 2026 which is in 92 days.
How were Medmira Inc’s earnings last quarter?
Medmira Inc released its earnings results on Apr 02, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Medmira Inc overvalued?
According to Wall Street analysts Medmira Inc’s price is currently Overvalued.
Does Medmira Inc pay dividends?
Medmira Inc does not currently pay dividends.
What is Medmira Inc’s EPS estimate?
Medmira Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medmira Inc have?
Medmira Inc has 701,730,600 shares outstanding.
What happened to Medmira Inc’s price movement after its last earnings report?
Medmira Inc reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.077%.
Which hedge fund is a major shareholder of Medmira Inc?
Currently, no hedge funds are holding shares in TSE:MIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medmira Inc
Medmira Inc. (MIR) is a Canadian biotechnology company primarily focused on the development and commercialization of rapid diagnostic tests for various infectious diseases. The company operates in the healthcare sector, specializing in point-of-care testing solutions that enable quick and accurate diagnosis of conditions such as HIV, Hepatitis, and other sexually transmitted infections. Medmira's core product offerings include its proprietary rapid test technologies, which are designed to provide reliable results with minimal equipment and training, catering to both clinical and non-clinical settings worldwide.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Sernova
―
NurExone Biologic
―
Defence Therapeutics
―
Options Prices
Currently, No data available
---